RT Journal Article SR Electronic T1 Long-term follow-up after bronchoscopic lung volume reduction valve treatment for emphysema JF ERJ Open Research JO erjor FD European Respiratory Society SP 00235-2022 DO 10.1183/23120541.00235-2022 VO 8 IS 4 A1 Jorine E. Hartman A1 Karin Klooster A1 T. David Koster A1 Nick H.T. ten Hacken A1 Marlies van Dijk A1 Dirk-Jan Slebos YR 2022 UL http://openres.ersjournals.com/content/8/4/00235-2022.abstract AB Background Multiple studies have shown that patients with severe emphysema can significantly benefit from bronchoscopic lung volume reduction endobronchial valve (EBV) treatment up to 1 year after treatment. However, hardly any data exist on longer term follow-up, especially on quality of life. Our aim was to investigate long-term follow-up after EBV treatment up to 3 years including quality of life in a real-life routine clinical setting.Methods We retrospectively included patients who underwent EBV treatment in our hospital in the Netherlands at least 3 years prior. Patients were invited for annual visits to our hospital, and spirometry, body plethysmography, 6-min walk distance (6MWD) test and St George's Respiratory Questionnaire (SGRQ) were performed during these visits.Results At 1-, 2- and 3-year follow-up, data were available from 189, 146 and 112 patients, respectively. Forced expiratory volume in 1 s, residual volume and SGRQ total score significantly improved up to 3 years after treatment compared with baseline, and 6MWD up to 2 years after treatment. In general, the magnitude of improvements gradually decreased over time.Conclusions Our results show that patients can benefit at least up to 3 years after EBV treatment. For the first time we found that patients can also benefit in terms of quality of life in the long term, which is an important outcome for this group of patients with end-stage COPD.A substantial number of patients still experience benefit 3 years after lung volume reduction treatment with endobronchial valves. This benefit includes quality of life, which is an important outcome for patients with end-stage COPD. https://bit.ly/3wqEZER